<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00034164</url>
  </required_header>
  <id_info>
    <org_study_id>SON-8184-1063</org_study_id>
    <nct_id>NCT00034164</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung Cancer</brief_title>
  <official_title>A Phase IIA Multicenter Evaluation of the Safety and Efficacy of Weekly Administration of S-8184 Paclitaxel Injectable Emulsion in Second Line Treatment of Patients With Relapsed Stage IIIB OR IV Non Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achieve Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achieve Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly
      S-8184 paclitaxel injectable emulsion in second line treatment of patients with relapsed
      stage IIIB or IV non small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goals of this study are to determine the objective response rate, to determine time to
      disease progression, duration of response, and survival, and to identify the maximum
      tolerated weekly dose and principal toxicities of S-8184 in this patient population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the objective response rate</measure>
    <time_frame>After all patients completed therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine time to disease progression</measure>
    <time_frame>After all patients completed therapy</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">52</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-8184 Paclitaxel Injectable Emulsion</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Histologic diagnosis of non small cell lung cancer

        Relapsed or unresectable stage IIIB or IV disease

        One and only one prior cytotoxic chemotherapy regimen which must have included a platinum
        agent dosed at 60 mg/m2 or higher per cycle for cisplatin and AUC 6 per cycle for
        carboplatin

        Documented response of at least stable disease while on first line therapy

        Adult (18 years of age or older) patients

        Adequate hematologic function (ANC greater than 1500 cells/mm3 and platelets greater than
        100,000/mm3)

        Serum creatinine less than 2.0 mg/dL

        Total bilirubin less than 1.5 mg/dL; SGOT and SGPT less than 3 times the upper limit of
        institutional normal values

        ECOG performance status of 0 - 2

        Bidimensional measurable or clinically evaluable disease

        Patients who have signed an IRB / Ethics Committee approved informed consent

        Life expectancy at least 12 weeks

        Patient has fully recovered from any previous surgery (at least 4 weeks since major
        surgery)

        Patient has a negative pregnancy test prior to study entry if premenopausal. (Patients of
        child bearing potential must use a medically effective form of contraception during the
        treatment.)

        Exclusion Criteria:

        Patients who have received any taxane-containing preparation including Taxol (paclitaxel)
        or Taxotere (docetaxel)

        Patients with intracranial metastases having neurologic function stabilized for less than 4
        weeks prior to study entry

        Females who are pregnant or lactating

        Patients with peripheral neuropathy NCI-CTC grade 2 or greater

        Patients who have received wide-field radiation, cytotoxic chemotherapy or hormonal therapy
        within 4 weeks of study entry; or mitomycin or nitrosoureas within 6 weeks of study entry

        Patients who have had an investigational agent within 4 weeks of study entry

        Patients receiving concurrent anticonvulsants known to induce P450 isoenzymes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>3 Cities</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.sonuspharma.com</url>
    <description>sponsor's home page</description>
  </link>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2002</study_first_submitted>
  <study_first_submitted_qc>April 23, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2002</study_first_posted>
  <last_update_submitted>June 2, 2009</last_update_submitted>
  <last_update_submitted_qc>June 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Monica Krieger, VP Regulatory Affairs</name_title>
    <organization>OncoGenex Pharmaceuticals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

